OBJECTIVE To compare early complication rates in unselected cases of coronary artery stenting in patients with stable v unstable angina.
SETTING Tertiary referral centre.
PATIENTS 390 patients with stable angina pectoris (SAP) and 306 with unstable angina (UAP). Patients treated for acute myocardial infarction (primary angioplasty) or cardiogenic shock were excluded.
INTERVENTIONS 268 coronary stents were attempted in 211 patients (30.3%). Stents used included AVE (63%), Freedom (14%), NIR (7%), Palmaz-Schatz (5%), JO (5%), and Multilink (4%). Intravascular ultrasound was not used in any of the cases. All stented patients were treated with ticlopidine and aspirin together with periprocedural unfractionated heparin.
RESULTS 123 stents were successfully deployed in 99 SAP patientsv 132 stents in 103 UAP patients. Failed deployment occurred with nine stents in SAP patients,v four in UAP patients (NS). Stent thrombosis occurred in four SAP patients and 11 UAP patients. Multivariate analysis showed no relation between stent thrombosis and clinical presentation (SAP v UAP), age, sex, target vessel, stent length, or make of stent. Stent thrombosis was associated with small vessel size (p < 0.001) and bailout stenting (p = 0.01) compared with elective stenting and stenting for suboptimal PTCA, with strong trends toward smaller stent diameter (p = 0.052) and number of stents deployed (p = 0.06). Most stent thromboses occurred in vessels < 3 mm diameter.
CONCLUSIONS Coronary artery stenting in unstable angina is safe in vessels ⩾ 3 mm diameter, with comparable initial success and stent thrombosis rates to stenting in stable angina.
- angina pectoris
Statistics from Altmetric.com
Coronary artery stenting in stable angina pectoris has become a widely accepted procedure in managing both vessel closure1 ,2 and suboptimal results3 ,4 after conventional balloon angioplasty (percutaneous transluminal coronary angioplasty, PTCA). Moreover in certain patient groups elective intracoronary stent implantation is more effective than simple PTCA alone.5 In stented vessels there is a low incidence of early vessel closure (stent thrombosis),6 and lower restenosis rates than with conventional PTCA.7 Acute coronary syndromes (acute myocardial infarction and unstable angina pectoris) are commonly associated with intracoronary thrombus.8 ,9 In these patients there are concerns about the use of intracoronary stents, and in particular about the risks of acute and subacute stent thrombosis.10 ,11 There is, however, a paucity of data comparing the results of stent implantation in patients with stable and unstable angina pectoris. The available studies give conflicting results, some suggesting an increased subacute stent thrombosis rate in unstable angina,10 ,12 but others suggesting there is no difference between stable and unstable angina.13 In this study we compare the rates of stent thrombosis and mortality in a group of consecutive unselected patients with stable or unstable angina pectoris.
Details about the patients are given in table 1. Between January 1996 and December 1996, coronary artery stenting was attempted in 211 (30.3%) of 696 consecutive coronary angioplasties performed for stable or unstable angina in our cardiac catheterisation laboratory. Our hospital has an immediate catchment of 325 000, and receives angioplasty referrals for a further 375 000. In all, 220 coronary vessels were stented, after 268 attempts; 99 of these patients were treated for stable angina and 103 for unstable angina (unstable angina was defined as angina at rest within the previous 72 hours). Seventeen of the vessels stented were saphenous vein bypass grafts. No internal mammary grafts were stented. Our study excluded all cases of primary angioplasty and salvage angioplasty for patients with acute myocardial infarction, and all patients with cardiogenic shock at the time of entry to the catheterisation laboratory. All patients were followed up for at least one month after stent implantation.
Lesion specific stenting was applied in all cases, with the majority of stents being AVE (63.5%), Freedom (14.1%), NIR (7.1%), Palmaz-Schatz (4.7%), and JO (4.7%). Smaller numbers of Multilink (4.3%), ACT1 (0.8%), Wiktor (0.4%), and Wallstents were implanted (0.4%). Choice of stent was determined by user preference, lesion length, vessel diameter, and tortuosity of the vessel. Angioplasty and coronary stent deployment were performed using standard techniques. Stent deployment was classified as bailout in situations of actual or threatened vessel closure, suboptimal in cases with a suboptimal result after balloon angioplasty (that is, limited dissection not threatening vessel closure, elastic recoil, or residual stenosis ⩾ 20%), and elective in patients in whom stent deployment was planned from the outset of the angioplasty procedure. All patients received oral aspirin (75−300 mg) before the start of the procedure. After insertion of the arterial sheath an intra-arterial bolus of 10 000 IU of heparin was given (a 5000 IU bolus in patients who were being treated with intravenous heparin at the start of the procedure). Additional 5000 IU intra-arterial boluses of heparin were given every hour throughout the angioplasty/stenting procedure. All lesions were predilated before stenting. Stents were either premounted or hand crimped on to the angioplasty balloon catheter. Final dilatation of the stent was performed with a balloon estimated to achieve a balloon to normal artery ratio of 1:1. No stents were deployed in vessels smaller than 2.5 mm diameter.
All the procedures were performed with high quality digital radiographic equipment. Final dilatation of the stent was performed either at nominal pressure or at high inflation pressures (> 12 atmospheres) to ensure optimal deployment. Intravascular ultrasound (IVUS) was not used in any case.
After the procedure an intravenous heparin infusion was begun (1250 IU/h) for a minimum period of 12 hours. The femoral sheaths were removed four to six hours after the discontinuation of heparin. Ticlopidine (250 mg twice daily) was started immediately after the procedure and continued for a period of one month under clinical monitoring. One patient was withdrawn from ticlopidine owing to skin reaction and started on oral anticoagulant treatment.
Vessel diameter was calculated predominantly using “eyeball” assessment and in cases of dispute the automated edge detection system, which is part of the digital cineangiographic system. Calibration was done using the 7 F guiding catheter before contrast injection. Measurement of the reference vessel diameter was made at the proximal part of the vessel nearest the stenosis except in ostial or bifurcational lesions, where the nearest normal vessel distal to the stenosis was measured.
All analyses were analysed by use of the Statgraphics software package. Data are expressed as means (SD). A multivariate analysis was performed to determine the predictors of stent thrombosis, taking p < 0.05 as significant. The factors used in this analysis were age, sex, operator, vessel stented, number of vessels stented, vessel diameter, stent diameter, stent indication (bailoutv suboptimal resultv elective), clinical presentation, number of stents implanted, stent length, make of stent, and maximum stent inflation pressure (high v nominal).
Demographic information is given in table 1: 80% of the patients were male; mean age was 61.4 years; mean vessel diameter was 3.3 cm. Most stents were implanted into either the left anterior descending coronary artery (LAD) or the right coronary artery (RCA), with fewer into circumflex, left main stem, or vein graft lesions (fig 2). There were no significant differences between sex, age, vessel or stent diameter (fig 3), or vessel treated between stable and unstable patients.
Intracoronary stents were deployed electively in 22 patients (two unstable v 20 stable), as bailout in 38 patients (21 unstable v 17 stable), and for a suboptimal angioplasty result in the remaining 142 patients (80 unstable v 62 stable). Thirteen stents failed to be deployed and were either withdrawn (4), lost into the peripheral circulation (5), or became stuck in the proximal coronary arteries (4, with three patients requiring emergency coronary bypass grafting). There was no significant difference between stable and unstable angina in terms of failed stent deployment. More stents were deployed electively in patients with stable angina (p < 0.05).
In all, 15 patients developed stent thrombosis, four with stable angina and 11 with unstable angina (12 male and three female patients, mean (SD) age 61.5 (6.8) years). Stent thrombosis occurred a mean of 81 (96) hours after stent implantation (range four hours to 14 days). Two patients died as a result of stent thrombosis.
PREDICTORS OF STENT THROMBOSIS
Using the multivariate regression model described above, significant predictors of stent thrombosis were smaller vessel size (p < 0.001) and indication for stent implantation (bailoutv suboptimal velective) (p = 0.014). Non-significant trends towards increased stent thrombosis were also observed with smaller stent diameter (p = 0.052), greater number of stents implanted (p = 0.06), lower maximum inflation pressure (p = 0.08), and with unstable presentation (p = 0.12).
STABLE v UNSTABLE ANGINA
Predictors for stent thrombosis were different in the two groups of patients. In patients with stable angina the only predictors of stent thrombosis were lower maximum inflation pressure (p = 0.02) and greater number of vessels stented (p = 0.03), whereas in patients with unstable angina the predictors were smaller vessel diameter (p = 0.001), indication for stent implantation (p = 0.012), stent diameter (p = 0.02), and greater number of stents implanted (p = 0.03).
Four patients (2.0%) died during or up to one month after stent implantation; in two, death was secondary to stent thrombosis. The only significant predictor of death in the multivariate model was the indication for stent implantation (p = 0.012)—that is, bailoutv suboptimal velective. Three deaths occurred in bailout stents compared with one suboptimal result stent.
No patient had repeat PTCA performed in the month following stent implantation except for those described above with stent thrombosis. In one patient with successful stent deployment for unstable angina coronary artery bypass grafting was performed in the follow up period.
Since the first description of intracoronary stent implantation in 198714 there has been considerable interest in factors predisposing to stent thrombosis, and in methods of preventing it. The majority of studies, however, have been in selected population groups, and may not, therefore, reflect general clinical scenarios. We examined an unselected group of consecutive patients with almost equal proportions of unstable and stable angina. The rate of stent thrombosis was 7.4% of all stenting procedures. The rate in stable angina was 3.8%, compared with 10.7% in unstable angina. This figure is in agreement with pooled data analysis, which estimates the rate of stent thrombosis in emergency situations to be 10.1% and in elective situations to be 4.3%.6 Our rate of stent thrombosis does, however, appear high compared with other recent publications, which estimate the rate of subacute stent thrombosis to be of the order of 3.4%15 to 5%.7 ,16 ,17 We feel that our overall rate reflects an unselected population with a high proportion of unstable patients. It thus included several high risk patients who would not have been entered into randomised trails. Most recent trials evaluating stent thrombosis only included haemodynamically stable patients with discrete lesions (< 15 mm length) in non-tortuous vessels > 3.0 mm diameter, and without intraluminal thrombus or involvement of bifurcation or ostium (for example, the Benestent trial).7 ,15 ,17 Other groups have shown a greater incidence of stent thrombosis during elective angioplasty in types of patient not enrolled in the Benestent study.18 If we simply excluded similar smaller vessels from the analysis then our rate of stent thrombosis would be reduced to 5.9%.
We found a higher rate of subacute stent thrombosis in patients with unstable angina than in stable angina. After multivariate regression analysis, however, the clinical presentation only had a weak, non-significant interaction with the development of stent thrombosis. The factors predisposing to stent thrombosis, in descending order, were smaller vessel size, bailout stenting, smaller stent diameter, and greater number of stents implanted. In the light of previous data on the high risk of stent thrombosis in small arteries,1 ,16 ,19 ,20 all operators had a high threshold for stent implantation in these patients, and hence the numbers are small in our dataset (6.8% of all vessels stented were ∼2.5 mm in diameter). Stent thrombosis developed in 26.7% of the vessels < 3.0 mm in diameter, and although there was no significant difference in the number of patients with 2.5 mm vessels between the groups with stable and unstable angina, the risks of stent thrombosis were particularly high in the unstable group (50% v 11.1%). It is generally thought that the high rate of stent thrombosis relates to lower blood flow and a greater percentage of metal to lumen area. It is likely that in this group the presence of thrombus, which is commonly found in unstable angina,8 ,9 acts as a further nidus for the formation of occlusive intraluminal thrombus.
It is well recognised that bailout stenting results in more stent thrombosis than elective stenting.10 ,21 ,22 It is accepted that there is a highly thrombotic intravascular environment in the situation of acute or threatened vessel closure, relating to vessel wall dissection, subintimal haemorrhage, vasoconstriction, low blood flow, and activation of both platelets and coagulation factors.23 In our dataset the rates of bailout stenting and stenting for suboptimal results were greater in patients with unstable angina. In the cohort overall, 18.4% of bailout stents subsequently thrombosed, compared with 6.3% of suboptimal stents and no elective stents. In patients with stable angina the rates were 11.8%, 4.8%, and 0% respectively, compared with 23.8%, 7.5%, and 0% in those with unstable angina. We feel that this at least partially explains the higher stent thrombosis rate in patients with unstable angina.
We found no relation between the length of the stent and the development of stent thrombosis, but a weak relation with greater numbers of stents implanted. There is very little information on either of these variables from reports of controlled studies. It is thought that greater length or number of stents may be more thrombogenic; one study showed a weak relation between stent length and stent thrombosis,1 other studies have not confirmed this.2 ,15 ,22 ,24 It is probable that multiple stenting is performed in longer lesions or longer dissections and therefore there is a greater underlying substrate for the development of intraluminal thrombus.
Stents from different manufacturers differ with respect to materials, strut diameters, lattice size, radial strength, and flexibility. Despite this we found no significant differences between the eight types of stent used during the course of this study with respect to stent thrombosis. Thrombosis occurred in 6.8% of all AVE stent implants, 5.6% of Freedom stents, 5.6% of NIR stents, 16.7% of Palmaz-Schatz stents, and not at all in the other stent types (presumably owing to the low numbers of those stents being deployed). No randomised controlled study has yet been performed with different stent types, but available data seem to suggest that there is little effect of stent make on the likelihood of stent thrombosis.6 ,25
The risk of stent thrombosis for LAD lesions was 11.2%, right coronary artery lesions 6.5%, circumflex lesions 0%, vein graft lesions 5.9%, and left main stem lesions 0%. These differences were not statistically significant in our study, but show similar trends to previous data which suggested that the risk of thrombosis was greatest in LAD lesions.26 The reason for this is unclear, although it could reflect more frequent deployment as a bailout procedure.27 In our patient population this was not the case; indeed the rate of stenting for bailout was 22% among LAD lesions compared with 23% in other vessels. This suggests that the increased stent thrombosis rate in LAD lesions may be related to other factors—for example, a less streamlined blood flow because of the increased number of branches and the greater tortuosity of this artery.
There was a weak (non-significant) relation between thrombosis and maximum stent inflation pressure. In all, 2.5% of stents that were inflated to high pressure (⩾ 12 atmospheres) subsequently thrombosed, compared with 8% of stents inflated only to nominal pressure. Recent studies using intravascular ultrasound have raised concerns over the adequacy of stent deployment at nominal balloon inflation pressures. Goldberg et al, using intravascular ultrasound imaging, found that only 12.5% of patients had complete stent deployment despite adequate angiographic findings.28 In view of this, many operators are now either deploying all stents at high pressure29 or using a combined intravascular ultrasound and balloon catheter approach.30
In all, four patients died within one month of intracoronary stent implantation, two as a direct result of stent thrombosis. The only variable having a predictive value for death was bailout stenting. Our rate of death following stent thrombosis (13.3%) compares with pooled data from numerous trials which suggest a rate of 12%.6
In summary, we found that the risk of subacute stent thrombosis is increased in unstable angina pectoris. In multivariate analysis, however, unstable angina was no longer significant as a predictor of stent thrombosis, which was principally related to stenting in small arteries and for bailout indications. The higher stent thrombosis rate in unstable angina can therefore be explained by factors other than the presentation alone. The rate of stent thrombosis was particularly high in patients with unstable angina who had stents deployed in small vessels (∼2.5 mm) or as a bailout procedure. Subacute stent thrombosis often occurs after hospital discharge10 ,15 ,26and is associated with a high mortality.6 Other treatments—for example, alternative antithrombotic regimens such as glycoprotein IIb/IIIa receptor antagonists (abciximab), should be investigated in the subset of patients at particularly high risk of stent thrombosis.
We would like to thank Benia Csaza for her assistance in collecting the data.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.